A 4-week, multicenter, double-blind, randomized, parallel group study to compare the gastrointestinal (GI) safety and tolerability of myfortic® and MMF (Cellcept®) when administered in combination with calcineurin inhibitors (CNI) in renal transplant recipients experiencing gastrointestinal intolerance (MyGAIN)

Sponsor: Novartis

Investigator: Bekir Tanriover, MD
Research Coordinator: Tina Worley, RN, BSN

Designated Site: Dallas Transplant Institute


The purpose of this study is to learn more about the experiences and symptoms associated with taking immunosuppressants following renal transplant surgery by switching approximately half of the patients to a delayed release formulation that is developed to alleviate GI symptoms.